BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8736808)

  • 1. The metabolic role of GIP: physiology and pathology.
    Morgan LM
    Biochem Soc Trans; 1996 May; 24(2):585-91. PubMed ID: 8736808
    [No Abstract]   [Full Text] [Related]  

  • 2. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastro-intestinal hormones GIP and GLP-1.
    Kieffer TJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):13-21. PubMed ID: 15122087
    [No Abstract]   [Full Text] [Related]  

  • 4. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
    Nauck MA; Baller B; Meier JJ
    Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central glucagon-like peptide-I in the control of feeding.
    Gunn I; O'Shea D; Turton MD; Beak SA; Bloom SR
    Biochem Soc Trans; 1996 May; 24(2):581-4. PubMed ID: 8736807
    [No Abstract]   [Full Text] [Related]  

  • 9. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
    Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
    Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
    Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
    FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut signals for islet hormone release.
    Ebert R
    Eur J Clin Invest; 1990 Oct; 20 Suppl 1():S20-6. PubMed ID: 2124993
    [No Abstract]   [Full Text] [Related]  

  • 15. [Endocrine system of the gastrointestinal tract. Pathophysiology with a clinical view].
    Skrha J
    Vnitr Lek; 2004 May; 50(5):392-8. PubMed ID: 15305639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glucagon-like peptides: a double-edged therapeutic sword?
    Perry T; Greig NH
    Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
    [No Abstract]   [Full Text] [Related]  

  • 17. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.
    Lynn FC; Pamir N; Ng EH; McIntosh CH; Kieffer TJ; Pederson RA
    Diabetes; 2001 May; 50(5):1004-11. PubMed ID: 11334402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin hormones and insulin secretion.
    Ahrén B; Gromada J; Schmitz O
    Horm Metab Res; 2004; 36(11-12):733-4. PubMed ID: 15655700
    [No Abstract]   [Full Text] [Related]  

  • 19. The enteroinsular axis.
    Marks V
    J Clin Pathol Suppl (Assoc Clin Pathol); 1978; 8():38-42. PubMed ID: 399610
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus.
    Clements RH; Gonzalez QH; Long CI; Wittert G; Laws HL
    Am Surg; 2004 Jan; 70(1):1-4; discussion 4-5. PubMed ID: 14964537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.